References
- Jordheim, L.P.; Durantel, D.; Zoulim, F.; Doumontet, C. “Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.” Nature Rev. Drug Discov. 2013, 12, 447.
- a) Prusoff, W.H. “Synthesis and biological activities of iododeoxyuridine, an analog of thymidine.” Biochim. Biophys. Acta. 1959, 32, 295. b) Ohishi, W.; Chayama, K. “Treatment of chronic hepatitis B with nucleos(t)ide analogues.” Hepatol. Res. 2012, 42, 219. (c) Fung, J., Lai, C-L.; Seto, W-K.; Yuen, M-F.; “Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B.” J. Antimicrob. Chemother. 2011, 66, 2715.
- De Clerq, E. “Highlights in Antiviral Drug Research: Antivirals at the Horizon.” Med. Res. Rev.. 2013, 33, 1215. (b) Kim, S.S.; Cheong, J.Y.; Cho, S.W.; “Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.” Gut Liver. 2011, 5, 278. c) Kukhanova, W.H.; “Anti-HIV nucleoside drugs: A retrospective view into the future.” Mol. Biol. 2012, 46, 768.
- a) Walton, E.; Jenkins, S.R.; Nutt, R.F.; Zimmerman, M.; Holly, F.W. “Branched-chain sugar nucleosides: a new type of biologically active nucleoside.” J. Amer. Chem. Soc. 1966, 88(19), 4524–4525. b) Eldrup, A.B.; Allerson, C.R.; Bennett, F.C.; Bera, S.; Bhat, B.; Bhat, N.; Bosserman, M.R.; Brooks, J.; Burlein, C.; Carroll, S.S.; Cook, D.P.; Getty, K.L.; MacCoss, M.; McMasters, D.R.; Olsen, D.B.; Prakash, T.P.; Prhavc, M.; Song, Q.; Tomassini, J.E.; Xia, J. “Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.” J. Med. Chem. 2004, 47(9), 2283–2295.
- (a) Sofia, M.J.; “Nucleotide prodrugs for the treatment of HCV infection.” Adv. Pharmacol. 2013, 57, 39. (b) Sofia, M.J.; Bao, D.; Chang, W.; Du, J.; Nagarathnam, D.; Rachakonda, S.; Reddy, P.G.; Ross, B.S.; Wang, P.; Zhang, H.-R.; Bansal, S.; Espiritu, C.; Keilmam, M.; Lam, A.M.; Micolochick Steuer, H.M.; Niu, C.; Otto, M.J.; Furman, P.A.; “Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.” J. Med. Chem. 2010, 53, 7202.
- a) Arasappan, A.; Njoroge, G.F.; Kwong, C.D.; Ananthan, S.; Bennett, F.; Clark, J.; Geng, F.; Girijavallabhan, V.; Huang, Y.; Kezar, H.S.; Maddry, J.A.; Reynolds, R.C.; Roychowdhury, A.; Fowler, A.T.; Secrist, J.A.; Kozlowski, J.A.; Shankar, B.B.; Tong, L.; Kim, S.; MacCoss, M. “Substituted pyrimidine derivatives and their use in treating viral infections.” PCT Int. Appl. 2011, WO 2011103441 A1 20110825. b) Girijavallabhan, V.; Alvarez, C.; Njoroge, F.G. “Regioselective cobalt-catalyzed addition of sulfides to unactivated alkenes.” J. Org. Chem. 2011, 76(15), 6442–6446.
- Usui, H.; Matsuda, A.; Ueda, T. “Synthesis of 8,2′-methanoguanosineand 9-(alpha-D-arabinofuranosyl)-8,2′-methano guanine (nucleosidesandnucleotides. LXVII).” Chem. Pharm. Bull. 1986, 34, (5), 1961–1967.
- a) Waser, J.; Gaspar, B.; Nambu, H.; Carreira, E.M. “Hydrazines andazides via the metal-catalyzed hydrohydrazination and hydroazidation of olefins.” J.Am. Chem. Soc. 2006, 128, 11693–11712. b) Gaspar, B.; Waser, J.; Carreira, E.M. “Cobalt-catalyzed synthesis of tertiary azides from alpha,alpha disubstituted olefins under mild conditions using commercially available reagents.” Synthesis. 2007, 24, 3839–3845. c) Waser, J.; Nambu, H.; Carreira, E.M. “Cobalt-catalyzed hydroazidation of olefins: convenient access to alkyl azides.” J.Am. Chem. Soc. 2005, 127, 8294–8295.
- Gaspar, B.; Carreira, E.M. “Mild cobalt-catalyzed hydrocyanation of olefins with tosyl cyanide.” Angew. Chem. Int. Ed. 2007, 46, 4519–4522.
- Hansen, S.G.; Jensen, H.H. Microwave irradiation as an effective means of synthesizing unsubstituted N-linked 1,2,3-triazoles from vinyl acetate and azides. Synlett. 2009, 20, 3275–3278.
- Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999, 285, 110–113.
- Furman, P.A.; Muramami, E.; Niu, C.; Lam, A.M.; Espiritu, C.; Bansal, S.; Bao, H.; Tolstykh, T.; Sreuer, H.M.; Keilman, M.; Zennou, V.; Bourne, N.; Veselenak, R.L.; Chang, W.; Ross, B.S.; Du, J.; Otto, M.J.; Sofia, M.J.; “Activity and themetabolic activation pathway of the potent and selective hepatitis Cvirus pronucleotide inhibitor PSI-353661.” Antiviral Res. 2011, 91, 120.
- a) Ludwig, J.; “A novel synthesis of nucleoside 5′-triphosphates.” Acta Biiochim. Biophys. Acad. Sci. Hung. 1981, 16, 131. b) Mishra, N.C.; Broom, A.D. “A novel synthesis of nucleoside 5′-polyphosphates.” J. Am. Chem. Soc., Chem. Commun. 1991, 18, 1276–1277.